Researchers at Vanderbilt University Medical Center have “turned back the clock” in a mouse model of metaplasia — precancerous stomach lesions — raising hopes that gastric cancer, a worldwide scourge that’s rising in the United States, can be prevented.

The gut has its own built-in pacemakers, populations of specialized cells that control smooth muscle contraction in the stomach, small intestine and colon.

Richard Peek, M.D., director of the Vanderbilt Digestive Disease Research Center, has been appointed to a five-year term as editor-in-chief of the medical journal Gastroenterology beginning July 2016.

A protein kinase linked to inflammation and tumor development may be a good target for gastric cancer therapies.

Children with stomach troubles grow up to be anxious adolescents and young adults, according to a recent study.

New information about signaling pathways involved in colorectal cancer could aid in assessing prognosis and identifying new therapeutic targets for the disease.

Molecular players involved in colon cancer progression could provide new biomarkers to indicate invasiveness and prognosis.